Pricing Log in Create free account
Friday 6 November 2026 Export RXRX’s income statement to Excel — free account

Recursion Pharmaceuticals, Inc.

RXRX Healthcare Biotechnology

Recursion Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $74.7 million, up 26.9% from fiscal 2024.

Revenue
+258.5%
EPS
+39.1%
Free cash flow
+33.8%
Total debt
−99.2%

Quarter to September 2026, against a year earlier

3.54 0.04 +1.14%
Market cap
$2.2B
P/E
0.0×
Fwd P/E
−4.6×
Dividend yield
—
F-score
3/9
Altman Z
0.37
Beneish M
−1.72
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 7.43
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell 5 3 4 4 3 3 5 1 1 2 2 1
Insider Ownership 0.00%

Capital & Financial Ratios $m

Size
Market Cap 2,180.00
Revenue ttm 68.23
Net income ttm (475.67)
Free cash flow ttm (314.47)
Net debt Q (556.42)
Valuation
P/E 0.00
Forward P/E (4.55) (negative: loss-making)
Price / sales 27.93 (above 10: high)
Forward P/S Powerpack
Price / FCF 0.00
Price / book 2.10
Financial health
Current ratio Q 5.01 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (20.00)
Growth
Revenue growth Q +258.49% (above 0%: growing)
Operating income growth Q +28.47% (above 0%: growing)
EPS, this year +38.81% (at or above 15%: strong)
EPS, next year A +6.04%
Revenue, next year A −44.06% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A +18.62% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 19.8×, against a ten-year median of 30.0×; over the ten years it ranged from 9.4× in 2023 to 500× in 2021.
P/S against its own 10 years 13.39%
10-year low 10-year high
P/B against its own 10 years 23.79%
10-year low 10-year high
EV/Sales against its own 10 years 15.89%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 395 597 748 557
Receivables 3 49 25 34
Inventory — — — —
Other 40 38 29 23
438 714 813 616
2023 2024 2025 Q'26
Payables 4 22 18 16
ST’ Debt — — — —
Other 36 62 38 16
93 187 148 123

Compound Annual Growth %

10y 5y 3y
Sales 41.51% 79.91% 23.30%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 30.85% 36.12% 32.53%

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate −0.24 Actual −0.22

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 −0.28 −0.21 Beat by 0.07
Q1 FY26 −0.30 −0.22 Beat by 0.08
Q2 FY26 −0.23 −0.25 Miss by 0.02
Q3 FY26 −0.24 −0.22 Beat by 0.02
Q4 FY26 −0.21 — Reports 24 February 2027

EPS $

Mar Jun Sep Dec Year
’26 (0.22) (0.25) (0.22) — —
’25 (0.50) (0.41) (0.36) (0.21) (1.44)
’24 (0.39) (0.40) (0.34) (0.53) (1.69)
’23 (0.34) (0.38) (0.43) (0.40) (1.58)
’22 (0.33) (0.38) (0.35) (0.31) (1.36)
’21 (1.33) (0.31) (0.28) (0.28) (1.49)
’20 (0.85) (0.87) (1.09) (1.17) (3.99)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 6 8 19 — —
’25 15 19 5 36 75
’24 14 14 26 5 59
’23 12 11 11 11 45
’22 5 8 13 14 40
’21 3 3 3 3 10
’20 0 0 1 3 4
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (81) (106) (77) — —
’25 (132) (76) (117) (46) (372)
’24 (102) (82) (59) (115) (359)
’23 (73) (67) (73) (74) (288)
’22 77 (62) (55) (45) (84)
’21 (31) (34) (33) (61) (159)
’20 (18) (17) (19) 9 (45)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (81) (108) (78) — —
’25 (134) (82) (118) (47) (380)
’24 (109) (86) (64) (117) (376)
’23 (79) (71) (74) (76) (300)
’22 73 (78) (63) (53) (121)
’22 — — — — (84)
’21 (50) (40) (43) (66) (198)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2.1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — — — 2 4 10 40 45 59 75 68 +78.4% 42 53 126 +19.1%
Gross margin, % — — — 100.00 100.00 100.00 (21.16) 4.46 23.12 4.99 29.21 (95.0) pt
EBT — — — (62) (87) (186) (239) (332) (465) (645) (480) +47.8%
EBT margin, % — — — (2,668.35) (2,196.01) (1,832.18) (601.05) (745.10) (789.93) (863.53) (703.82) +1,804.8 pt
Net income — 0 — (62) (87) (186) (239) (328) (464) (645) (476) n/m
Per share, $
Per share, $ Revenue — — — 0.11 0.18 0.08 0.23 0.21 0.21 0.17 0.13 +7.6%
Earnings — — — (2.87) (3.99) (1.49) (1.36) (1.58) (1.69) (1.44) (0.90) (10.9%)
Cash flow — — — (2.64) (2.08) (1.27) (0.48) (1.38) (1.31) (0.83) (0.57) (17.5%)
Capex — — — (0.18) (0.31) (0.32) (0.21) (0.06) (0.06) (0.02) (0.01) (31.2%)
Free cash flow — — — (2.83) (2.39) (1.58) (0.69) (1.44) (1.37) (0.85) (0.58) (18.1%)
Book value — — — 3.56 11.11 4.33 2.77 2.23 3.77 2.53 1.67 (5.6%)
Shares, m — — — 22 22 125 176 208 274 447 513 +65.8%
Valuation, ×
Valuation, × P/E — — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S — — — 111.54 111.54 283.62 33.26 46.02 31.50 24.51 27.93 91.7
P/B — — — 0.00 0.00 5.32 2.73 4.43 1.79 1.62 2.10 2.3
EV/Sales — — — 79.24 79.24 232.78 19.44 37.19 21.67 14.62 19.78 69.2
EV/FCF — — — (6.18) (6.18) (11.94) (6.41) (5.52) (3.39) (2.87) (4.29) (6.1)
Cash, $m
Cash, $m Operating cash flow — — — (57) (45) (159) (84) (288) (359) (372) (311) +36.7%
Capex — — — (4) (7) (40) (37) (13) (17) (9) (4) +14.1%
Free cash flow — — — (61) (52) (198) (121) (300) (376) (380) (314) +35.7%
Balance, $m
Balance, $m Working capital — — — 70 243 488 470 345 527 665 493 +45.6%
Net debt — — — (63) (253) (517) (551) (394) (578) (738) (556) +50.8%
Shareholders’ equity — — — 77 242 543 486 463 1,035 1,131 906 +56.5%
Returns, %
Returns, % ROA — — — (61.01) (43.50) (41.03) (36.52) (48.42) (44.11) (44.12) (36.29) +16.9 pt
ROIC — — — (276.95) 0.00 (448.73) 0.00 (313.71) (65.59) (103.19) (88.54) +173.8 pt
ROE — — — 49.80 52.64 (110.79) (46.56) (69.12) (61.89) (59.54) (48.72) (109.3) pt
People
People Employees — — — — 331 400 500 500 800 600 — +12.6%
Revenue/emp, $m — — — 0.00 0.01 0.03 0.08 0.09 0.07 0.12 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

Recursion Pharmaceuticals, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
ADMA ADMA Biologics Inc $3.0B 16.7× 14.0× +5.12% (above 0%: growing) +46.67% (above 0%: growing) +1,709.49% (above 0%: growing) 70.81% 48.02% Compare
VCEL Vericel Corporation $2.7B 77.8× 72.9× +26.47% (above 0%: growing) +180.00% (above 0%: growing) −19.39% (below 0%: shrinking) 73.34% 14.27% Compare
MBX MBX Biosciences, Inc. $2.3B — (loss-making) — — n/m −29.67% (below 0%: shrinking) — 0.00% Compare
PHVS Pharvaris N.V. $2.3B — (loss-making) — — n/m −17.31% (below 0%: shrinking) 0.00% 0.00% Compare
NAMS NewAmsterdam Pharma Company N.V. $2.3B — (loss-making) — (loss-making) +5,406.90% (above 0%: growing) n/m −21.76% (below 0%: shrinking) 100.00% (230.58%) Compare
PVLA Palvella Therapeutics, Inc. $2.3B — (loss-making) — (loss-making) −99.09% (below 0%: shrinking) n/m −136.38% (below 0%: shrinking) 100.00% 0.00% Compare
CLDX Celldex Therapeutics, Inc. $2.2B — (loss-making) — (loss-making) −96.83% (below 0%: shrinking) n/m −35.45% (below 0%: shrinking) 100.00% (366,468.18%) Compare
RXRX Recursion Pharmaceuticals, Inc. $2.2B — (loss-making) — (loss-making) +258.49% (above 0%: growing) n/m +33.83% (above 0%: growing) 45.85% (663.95%)
BHVN Biohaven Ltd. $2.1B — (loss-making) — (loss-making) +131.43% (above 0%: growing) n/m +26.55% (above 0%: growing) 0.00% 0.00% Compare
Median of peers $2.3B — — +15.80% — −20.57% 73.34% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 30 April 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 9.61m 3.48m 13.07
2024 8.50m 1.91m 21.60
2023 8.61m 10.68m 31.50
2022 6.32m (5.83m) 24.63
2021 673.59k 21.79m 54.73

Ownership

Directors and executive officers, together 14.60% of the votes
Christopher Gibson 9.90% of the votes
The Vanguard Group 8.20% of the votes
BlackRock Inc. 6.60% of the votes
ARK Investment Management LLC 6.50% of the votes
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Recursion Pharmaceuticals, Inc. (RXRX) Latest News

4 Nov

Impact 3 · · Simply Wall St.
Impact 3 · · Simply Wall St.
Impact 3 · · Zacks

3 Nov

Impact 3 · · Moby
Impact 3 · · The Motley Fool transcript
Impact 3 · · MarketBeat
Impact 3 · · Zacks

2 Nov

Impact 4 · · GlobeNewswire
Impact 3 · · GlobeNewswire

29 Oct

Impact 4 · · Zacks

28 Oct

Impact 3 · · Zacks

26 Oct

Impact 4 · · GlobeNewswire
Impact 3 · · Zacks

20 Oct

Impact 3 · · Zacks

18 Oct

Impact 4 · · Simply Wall St.
Impact 4 · · Simply Wall St.
Impact 4 · · Simply Wall St.
Impact 3 · · Simply Wall St.
Impact 3 · · Simply Wall St.

15 Oct

Impact 4 · · Insider Monkey
Impact 4 · · Stocktwits
Impact 4 · · GlobeNewswire
Impact 4 · · GlobeNewswire
Impact 3 · · Simply Wall St.
Impact 3 · · GlobeNewswire

12 Oct

Impact 3 · · Zacks
Impact 3 · · Zacks

8 Oct

Impact 3 · · Trefis

6 Oct

Impact 3 · · Zacks

28 Sep

Impact 3 ·

RXRX metrics, ten years each

stockrow.com/RXRX · Data as of Nov 5, 2026 · For information only; not investment advice. · © 2026 stockrow.com